证券代码：000718 证券简称：苏宁环球 苏宁环球股份有限公司 投资者关系活动记录表 编号：2023-002 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 业绩说明会  | | | □新闻发布会 路演活动 | | 动类别 | □现场参观 □战略发布会 | | | □其他 | | 活动参与人员 | 通过深圳证券交易所"互动易"平台 （http://irm.cninfo.com.cn）"云访谈"栏目参 | | | 加公司 2022 年度业绩说明会的投资者； | | | 公司董事长张桂平先生、董事会秘书蒋立波先生、 | | | 财务负责人刘得波先生、独立董事俞红海先生 | | 时间 | 2023 年 5 月 9 日 | | 地点 | 深圳证券交易所"互动易"平台 | | | （http://irm.cninfo.com.cn）"云访谈"栏目 | | 形式 | 网上业绩说明会 公司就投资者在本次业绩说明会召开过程中提 | | 交流活动主要 | 出的问题进行了回复，本次业绩说明会不涉及应披 露的重大信息。具体如下： 1、请问董秘，如何看待公司 2022 年 ...

Financial Performance - Total revenue for Q1 2023 was CNY 433,602,663.50, a decrease of 9.03% compared to CNY 476,659,221.01 in the same period last year[5] - Net profit attributable to shareholders was CNY 126,809,928.58, down 4.42% from CNY 132,669,907.73 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.0418, reflecting a decline of 4.35% compared to CNY 0.0437 in the previous year[5] - Net profit for Q1 2023 was ¥126,264,061.14, slightly down from ¥130,789,912.30, representing a decrease of 3.93%[25] - The total comprehensive income attributable to the parent company was CNY 126,809,928.58, a decrease from CNY 132,669,907.73 in the previous period[27] Cash Flow - Net cash flow from operating activities decreased significantly by 87.83%, from CNY 158,851,768.09 to CNY 19,326,758.38[5] - Cash inflow from operating activities totaled CNY 708,622,922.07, compared to CNY 633,536,801.09 in the prior period, reflecting an increase of approximately 11.84%[28] - Cash outflow from operating activities was CNY 689,296,163.69, up from CNY 474,685,033.00, resulting in a net cash flow from operating activities of CNY 19,326,758.38, down from CNY 158,851,768.09[28] - Cash inflow from investing activities was CNY 1,000,379.15, significantly lower than CNY 30,263,313.27 in the previous period[29] - Cash outflow from investing activities totaled CNY 3,737,572.00, compared to CNY 320,553,266.00 in the prior period, leading to a net cash flow from investing activities of -CNY 2,737,192.85[29] - Cash inflow from financing activities was CNY 494,860,942.75, down from CNY 755,539,578.00 in the previous period[29] - Cash outflow from financing activities increased to CNY 825,016,984.73 from CNY 486,073,044.03, resulting in a net cash flow from financing activities of -CNY 330,156,041.98[29] - The ending balance of cash and cash equivalents was CNY 438,690,178.56, compared to CNY 362,115,895.53 at the end of the previous period[29] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 15,121,034,263.72, a decrease of 1.76% from CNY 15,392,539,894.54 at the end of the previous year[5] - Total current assets decreased to ¥11,478,866,543.86 from ¥11,725,115,191.74, indicating a reduction of approximately 2.1%[18] - Total liabilities decreased to ¥5,215,334,641.79 from ¥5,613,104,333.75, a reduction of 7.07%[22] - The company's equity attributable to shareholders increased by 1.33% to CNY 9,632,622,975.07 from CNY 9,505,813,046.49[5] - The equity attributable to shareholders of the parent company increased to ¥9,632,622,975.07 from ¥9,505,813,046.49, an increase of 1.34%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 88,536[12] - The total number of unrestricted shares held by the top 10 shareholders was 529,966,134 shares, with Suning Universal Group Co., Ltd. being the largest shareholder[16] - The company has a significant number of shares held through margin trading, with Huatai Securities Asset Management holding 45,809,748 shares[16] Operational Insights - Operating income from non-recurring items increased significantly by 275.56% to CNY 3,523,689.06, up from CNY 938,242.72 year-on-year[11] - The company reported a government subsidy of CNY 282,550.68, which is closely related to its regular business operations[6] - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the report[17] - The report indicates a focus on enhancing operational efficiency and financial stability moving forward[17] Financial Expenses - Financial expenses rose by 53.91% to CNY 23,379,600.52, compared to CNY 15,190,869.41 in the same period last year[11] - The company reported a financial expense of ¥23,379,600.52, up from ¥15,190,869.41, an increase of 54.56%[23] Inventory and Receivables - Accounts receivable increased to ¥87,508,050.97 from ¥74,294,720.85, reflecting a growth of about 17.5%[18] - The company's inventory stood at ¥9,463,631,438.65, up from ¥9,390,077,575.16, showing an increase of about 0.8%[18] - The total amount of other current assets was ¥674,819,715.19, an increase from ¥629,125,170.15, reflecting a growth of approximately 7.3%[18] Audit Status - The first quarter report was not audited[30]

证券代码：000718 证券简称：苏宁环球 公告编号：2023-022 苏宁环球股份有限公司 关于召开 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 苏宁环球股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在巨潮资讯网披露了公司《2022 年年度报告》。为增进公司与广大 投资者之间的沟通交流，便于广大投资者更加全面深入地了解公司 2022 年度经营业绩及未来发展情况，公司定于 2023 年 5 月 9 日（星期 二）举办 2022 年度网上业绩说明会，现将相关事项公告如下： 一、召开说明会的时间 2023 年 5 月 9 日（星期二）下午 15：00-17：00 电话：025-83247946 邮箱：suning@suning.com.cn 特此公告。 出席本次网上业绩说明会的人员有：公司董事长张桂平先生，董事、 副总裁、董事会秘书蒋立波先生，独立董事俞红海先生，财务负责人刘 得波先生。 三、投资者参与方式 投资者可通过登陆深圳证券交易所"互动易"平台 （http://irm.cninfo.com.cn ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥2.24 billion, a decrease of 25.12% compared to ¥2.99 billion in 2021[6]. - The net profit attributable to shareholders for 2022 was approximately ¥358 million, down 42.07% from ¥618 million in 2021[6]. - The basic earnings per share for 2022 was ¥0.1180, a decline of 42.04% from ¥0.2036 in 2021[6]. - The net cash flow from operating activities increased by 110.61% to approximately ¥794 million in 2022, compared to ¥377 million in 2021[6]. - The gross profit margin improved to 62.5%, up 4.22% from the previous year, demonstrating enhanced profitability[57]. - In 2022, the company achieved total revenue of CNY 2.24 billion, a decrease of 25.12% year-on-year, and a net profit of CNY 358 million, down 42.07% year-on-year, with a net profit margin of 15.99%[56]. Dividend Distribution - The company plans to distribute a cash dividend of 1.20 RMB per 10 shares to all shareholders, based on a total of 3,034,636,384 shares[4]. - The profit distribution plan for 2022 proposes a cash dividend of 1.20 CNY per 10 shares (before tax) based on a total share capital of 3,034,636,384 shares[149]. - The cash dividend represents 100% of the total distributable profit of RMB 4,934,217,638.99 for the reporting period[150]. - No stock dividends or capital reserve transfers to increase share capital are proposed, with remaining undistributed profits carried forward to the next year[151]. Business Transformation - The company has undergone a significant business transformation since its listing, shifting from paper production to real estate development[23]. - The company is focusing on transitioning to biomedicine and anti-aging medical services while maintaining steady development in its core real estate business[38]. - The company plans to focus on the biopharmaceutical industry and anti-aging regenerative medicine as strategic transformation directions for higher quality development in 2023[109]. Real Estate Market Challenges - The real estate market faced significant challenges in 2022, with a 24.30% decrease in sales area and a 26.70% decrease in sales revenue year-on-year[38]. - The company is optimistic about a gradual recovery in the real estate market, with a narrowing decline in sales for top real estate companies to 4.8% in early 2023[39]. - The total investment in real estate development reached CNY 13.28 trillion in 2022, a year-on-year decrease of 10%[40]. - The transaction area and amount of residential land in 300 cities across the country fell by over 30% year-on-year in 2022, reaching a near ten-year low[40]. Operational Efficiency - The company aims to enhance project management, marketing, and risk control to maintain healthy development in the real estate and medical beauty sectors[44]. - The company will utilize 931,609,900 CNY of surplus fundraising and interest income for permanent working capital supplementation[103]. - The company aims to enhance operational efficiency and maintain a healthy financial status while optimizing debt structure and financing costs[110]. Corporate Governance - The company maintains a governance structure that ensures clear responsibilities and effective checks and balances among the board, supervisory board, and management[117]. - The company has established a robust investor relations management system, ensuring timely and accurate information disclosure to all investors[119]. - The company respects and protects the rights of shareholders, customers, employees, and other stakeholders, promoting harmonious development[120]. - The company held three shareholder meetings during the reporting period, with participation rates of 56.29%, 56.33%, and 54.16% respectively[122][124]. Employee Management - The total number of employees at the end of the reporting period is 997, with 288 in production, 203 in sales, 270 in technology, 66 in finance, and 170 in administration[145]. - The company emphasizes a performance-based salary system, ensuring competitive compensation levels within the industry[146]. - The company has implemented an employee stock ownership plan to enhance long-term incentive mechanisms[146]. Financial Position - Total assets at the end of 2022 were approximately ¥15.39 billion, a slight decrease of 0.33% from ¥15.44 billion at the end of 2021[6]. - The asset-liability ratio stood at 36.47%, significantly better than the industry average, reflecting a strong financial position[57]. - The company reported a total financing balance of RMB 2,199,673,100, with an average financing cost ranging from 4.9% to 8%[50]. Market Presence - The company has developed nearly 100 real estate projects, covering over 10 million square meters, enhancing its brand recognition and reputation nationwide[53]. - The company has ongoing real estate development projects in Nanjing, Shanghai, Jilin, and Yixing, focusing on quality improvement and efficiency enhancement[44]. - The company has established a strong customer base with high loyalty and activity levels, which helps improve product gross margins[54]. Regulatory Compliance - The company strictly adheres to legal regulations and its articles of association in conducting shareholder meetings, ensuring equal rights for all shareholders[117]. - The company has not reported any major defects in non-financial reporting[159]. - The company reported no significant environmental violations or administrative penalties during the reporting period[161]. Related Party Transactions - The company reported a significant related party transaction amounting to 113.6 million yuan, representing 16.52% of similar transactions[178]. - The company engaged in a related party transaction for construction services with a total amount of 75.68 million yuan, which is 7.57% of the total[178]. - The company has no significant guarantees or related party guarantees during the reporting period[189].

Financial Performance - The company's operating revenue for Q3 2022 was CNY 678,139,121.13, representing a year-on-year increase of 0.17%[6] - Net profit attributable to shareholders for Q3 2022 was CNY 163,010,235.01, an increase of 48.67% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 158,492,704.19, up 215.17% year-on-year[6] - Total operating revenue for Q3 2022 was CNY 1,810,268,777.98, a decrease of 25.7% compared to CNY 2,437,217,857.22 in the same period last year[21] - Net profit for Q3 2022 was CNY 488,064,984.96, a decline of 33.5% compared to CNY 734,458,335.48 in Q3 2021[23] - Total comprehensive income for the period was approximately ¥488.06 million, down from ¥734.46 million in the previous period, representing a decrease of about 33.5%[24] - Basic and diluted earnings per share were both ¥0.1621, compared to ¥0.2443 in the same period last year, reflecting a decline of approximately 33.5%[24] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to CNY 15,687,373,978.35, reflecting a 1.58% increase from the end of the previous year[6] - Total assets increased to CNY 15,687,373,978.35, up from CNY 15,442,762,867.48 at the end of the previous quarter[20] - Total liabilities decreased to CNY 6,075,597,448.78 from CNY 6,360,832,018.03 in the previous quarter[20] - The company's equity attributable to shareholders rose to CNY 9,356,121,995.87, compared to CNY 8,822,676,795.23 in the previous quarter[20] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 612,224,607.73, an increase of 38.74%[6] - The company’s cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[21] - Cash inflow from operating activities totaled approximately ¥2.14 billion, down from ¥2.62 billion, indicating a decrease of about 18.3%[25] - Cash outflow from investing activities resulted in a net cash flow of -¥192.22 million, compared to a positive cash flow of ¥363.19 million in the previous year[26] - Cash inflow from financing activities was approximately ¥1.20 billion, a decrease from ¥1.92 billion in the previous year, representing a decline of about 37.5%[26] - The ending balance of cash and cash equivalents was approximately ¥435.37 million, down from ¥871.18 million, indicating a decrease of about 50%[26] - The company received cash from the issuance of loans amounting to ¥749 million, down from ¥1.64 billion in the previous year[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 95,662[14] - The largest shareholder, Suning Universal Group, held 21.20% of the shares, with 487,609,998 shares pledged[14] - The top ten unrestricted shareholders hold a total of 1,020,000,000 shares, with Suning Global Group holding the largest share of 643,312,165[15] - The company’s repurchase account holds 227,774,577 shares, accounting for 7.51% of the total share capital[15] Strategic Initiatives - The company approved the second employee stock ownership plan in 2022 to enhance the long-term incentive mechanism, aiming to boost employee engagement and competitiveness[16] - The company is focused on market expansion and new product development as part of its strategic initiatives[16] - The company plans to focus on market expansion and new product development to drive future growth[21] Inventory and Receivables - The company reported a significant increase in receivables, with accounts receivable rising to CNY 134,522,191.52 from CNY 110,883,218.10, a growth of approximately 21.3%[17] - The company's inventory decreased to CNY 9,678,518,304.36 from CNY 9,923,035,697.37, indicating a reduction of about 2.5%[17] Financial Health - The company reported a significant increase in trading financial assets, which rose by 410.22% to CNY 236,316,250.97[12] - Short-term borrowings increased by 54.37% to CNY 692,600,000.00 due to new short-term loans taken during the year[12] - The company’s financial health is supported by a robust liquidity position, with total current assets significantly exceeding current liabilities[17] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 1.76%, a decrease of 0.34% compared to the previous year[6] - Cash and cash equivalents increased to CNY 755,494,847.03 from CNY 452,859,447.43 at the beginning of the year, reflecting a growth of approximately 66.8%[17] - The long-term equity investments stood at CNY 1,243,774,994.70, slightly down from CNY 1,250,847,101.45[17] - The company reported a decrease in accounts payable to CNY 1,899,209,427.88 from CNY 2,180,004,201.68 in the previous quarter[20] Audit Status - The report for the third quarter was not audited[27]

Financial Performance - The company's operating revenue for the reporting period was CNY 1.13 billion, a decrease of 35.67% compared to the same period last year[39]. - The net profit attributable to shareholders was CNY 328.75 million, down 47.86% year-on-year, with a net profit margin of 29.04%[39]. - The cash flow from operating activities increased significantly by 391.00% to CNY 327.89 million compared to the previous year[39]. - The total assets at the end of the reporting period were CNY 16.03 billion, reflecting a 3.82% increase from the end of the previous year[39]. - The company reported a total revenue of 11,176 million yuan for the first half of 2022, representing a year-on-year increase of 78.57%[116]. - The company reported a total revenue of 4.3 billion yuan for the first half of 2022, which is a 9.9% increase compared to the same period last year[190]. - The net profit attributable to shareholders for the first half of 2022 was 1.1 billion yuan, reflecting a year-on-year increase of 14.3%[190]. - The total comprehensive income for the first half of 2022 was reported at 630.58 million yuan, a decrease of 6.8% compared to the previous period[190]. Shareholder Information - The company reported a total of 2,806,861,807 shares as the basis for profit distribution, with a cash dividend of 0.50 RMB per 10 shares (including tax) proposed[4]. - The total number of ordinary shareholders at the end of the reporting period was 103,391[141]. - The largest shareholder, Suning Universal Group Co., Ltd., held a 22.36% stake, amounting to 678,497,765 shares, with 487,609,900 shares pledged[141]. - Zhang Guiping, a natural person, held 17.27% of the shares, totaling 524,179,100 shares, with 135,544,700 shares pledged[141]. - The company is committed to maintaining a minimum cash dividend ratio of 80% in profit distributions, aligning with its shareholder return strategy[95]. Investment and Projects - The company is focusing on diversifying into the biomedicine and anti-aging sectors, with increasing revenue and profit contributions from its medical beauty segment[40]. - The company plans to enhance its investment in the biomedicine industry and strengthen its competitive advantage in the medical beauty value chain[40]. - The company has ongoing projects with a total investment amount of 60 million yuan and a cumulative investment of 28.69 million yuan in Jilin's residential project[42]. - The company reported a cumulative investment of RMB 1,176 million in the Water City project, with an expected return of RMB 2,500 million[70]. - The company has invested RMB 4,686 million in the Silicon Valley project, with an expected return of RMB 2,000 million[70]. Financial Management - The total financing balance is approximately CNY 2.92 billion, with bank loans accounting for CNY 2.52 billion at an interest rate range of 3.89% to 8.00%[45]. - The average financing cost for the company is approximately 6% per annum, which is lower than the industry average[49]. - The company reported a significant reduction in financial expenses, decreasing to CNY 10,350,742.92 from CNY 27,399,719.17, a drop of 62.2%[170]. - The company has allocated 999 million yuan for special reserves, indicating a proactive approach to financial management[194]. Market and Economic Conditions - The real estate market faced significant challenges, with a 5.4% decline in real estate development investment nationwide during the first half of 2022[37]. - The overall real estate market is expected to stabilize in the second half of the year, supported by government policies aimed at boosting buyer confidence[38]. - The company is closely monitoring macroeconomic conditions and industry policies, as uncertainties in the economy could significantly affect its operations and profitability[85]. Corporate Governance and Compliance - The company emphasizes the accuracy and completeness of the financial report, with all board members present for the meeting[4]. - The company adheres to legal requirements for corporate governance, enhancing internal control systems and improving information disclosure quality[102]. - There were no significant legal disputes or administrative penalties reported during the reporting period[112]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[108]. Employee Relations - The company implemented an employee stock ownership plan to enhance long-term incentive mechanisms, boosting management and employee motivation[42]. - The company has established a competitive compensation and benefits system, ensuring fair and just performance evaluation mechanisms for employees[102]. - The company has not implemented any employee stock ownership plans during the reporting period, with no shares held by employees at the end of the period[97]. Strategic Focus - The company plans to continue its strategic transformation towards the biopharmaceutical sector while maintaining its real estate business[51]. - The company is focusing on expanding its market presence and enhancing its investment strategies through various projects[70]. - The company plans to expand its market presence by launching new products and enhancing its technology development initiatives[190]. - The company is focusing on strategic mergers and acquisitions to enhance its competitive position in the market[190].

Financial Performance - The company's operating revenue for 2021 was approximately ¥2.99 billion, a decrease of 32.31% compared to ¥4.42 billion in 2020[27]. - The net profit attributable to shareholders for 2021 was approximately ¥617.85 million, down 41.66% from ¥1.06 billion in 2020[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥592.23 million, a decline of 44.14% from ¥1.06 billion in 2020[27]. - The total assets at the end of 2021 were approximately ¥15.44 billion, a decrease of 4.16% from ¥16.11 billion at the end of 2020[29]. - The net assets attributable to shareholders increased by 4.70% to approximately ¥8.82 billion at the end of 2021, compared to ¥8.43 billion at the end of 2020[29]. - The company reported a basic earnings per share of ¥0.2036 for 2021, down 41.66% from ¥0.3490 in 2020[27]. - The weighted average return on equity for 2021 was 7.07%, a decrease of 5.68% from 12.75% in 2020[27]. - The company's debt-to-asset ratio, excluding advance receipts, stands at 39.24%, with a net debt ratio of 22.97%, reflecting a healthy financial status[54]. - The gross profit margin increased from 34% in 2016 to 58% in 2021, while the net profit margin rose from 13% to 20% during the same period, showcasing steady improvement in profitability[55][56]. Business Transformation and Strategy - The company has undergone a significant business transformation since its listing, shifting its primary business focus from paper production to real estate development in December 2005[26]. - The company’s main business operations have been restructured following a major asset reorganization in December 2005, changing its controlling shareholder to Suning Universal Group[26]. - The company has a diversified portfolio, including real estate development and various subsidiaries in different sectors[16]. - The company is focusing on the biopharmaceutical sector as a key direction for transformation, with significant investments and acquisitions in the medical aesthetics industry to enhance growth potential[58]. - The company is exploring new development models in response to regulatory changes in the real estate sector, aiming for sustainable growth[42]. - The company has a strategic focus on high-quality projects, leveraging brand and platform advantages to enhance its market position[43]. - Future outlook includes a commitment to meet reasonable housing demands and promote healthy development in the real estate market[42]. - The company is actively pursuing market expansion opportunities in various cities to diversify its portfolio[43]. Real Estate Market Insights - The company operates primarily in the real estate sector, focusing on the Nanjing market while also having a presence in Shanghai, Jilin, Yixing, and Xi'an[43]. - Total land reserves amount to 186.63 million square meters, with a total building area of 226.86 million square meters and remaining developable area also at 226.86 million square meters[46]. - The company has several key projects under development, including the Nanjing Water City project, which has a completion rate of 90% and a total investment of 128 million yuan[46]. - In the reporting period, the company achieved a cumulative pre-sale area of 332,370 square meters for the Nanjing Tianrun project, generating a revenue of 1,396 million yuan[47]. - The real estate market faced significant fluctuations in 2021, with a total sales area of 1.794 billion square meters, a year-on-year growth of only 1.9%[40]. - The new construction area in 2021 decreased by 11.4% year-on-year, marking the largest decline since 2016[41]. - Real estate sector contributed ¥2.59 billion, accounting for 86.74% of total revenue, down 35.80% from ¥4.04 billion in 2020[60]. - Gross profit margin for the real estate sector was 59.29%, a decrease of 1.33% year-over-year[64]. Investment and Financial Management - The company reported total assets of approximately RMB 15.443 billion and annual revenue of about RMB 2.99 billion, with a profit margin of approximately 8.97 billion RMB, indicating strong financial performance[53]. - The average financing cost for the company in 2021 was maintained at a low level of 6.45%, supporting its sustainable development strategy[54]. - The company plans to continue launching projects such as Binjiang Yayuan and Tianhua Silicon Valley Phase III to maintain strong profitability levels[56]. - The company has provided a total of RMB 428.698 million in mortgage guarantees for homebuyers, indicating its commitment to supporting customers[51]. - The company has achieved a 100% rental rate for several key projects, including the Green Valley and Silicon Valley in Nanjing, demonstrating effective asset management[52]. - The company emphasizes a strategy of low debt and high returns, aiming for a healthy and sustainable operational model[52]. - The company reported a significant increase in user data, reflecting a growing customer base and demand for its properties[47]. - The company is investing in new technologies and product development to enhance operational efficiency and customer satisfaction[47]. Corporate Governance and Shareholder Relations - The company ensures that all shareholders, especially minority shareholders, can exercise their rights equally and fully[124]. - The company maintains independence from its controlling shareholder in personnel, assets, finance, organization, and business operations[127]. - The board of directors strictly follows legal and regulatory requirements in its operations and decision-making processes[125]. - The company has established a financial management center and an independent accounting system to ensure financial independence[127]. - The company emphasizes transparency in information disclosure, adhering to legal and regulatory standards[126]. - The company has implemented measures to protect the legitimate rights and interests of all stakeholders, promoting sustainable development[126]. - The company held its annual general meeting on April 29, 2021, with a participation rate of 57.01%[130]. - The first extraordinary general meeting of 2021 was held on July 8, 2021, with a participation rate of 43.69%[130]. - The second extraordinary general meeting of 2021 took place on August 12, 2021, with a participation rate of 2.73%[130]. Employee and Operational Management - The company reported a total of 1,063 employees at the end of the reporting period, with 413 in production, 140 in sales, 207 in technology, 80 in finance, and 223 in administration[159]. - The company has conducted various training programs to enhance management and professional skills among employees[163]. - The company has adopted a competitive salary policy based on individual capabilities and market value, ensuring compliance with labor laws[162]. - The total remuneration for the board of directors and senior management during the reporting period amounted to 810.05 million yuan[146]. - Zhang Guiping, the chairman and president, received a total pre-tax remuneration of 273.17 million yuan[146]. Risk Management and Compliance - The company emphasizes the importance of adhering to safety production management and risk control measures[113]. - The company has established a comprehensive internal control system to effectively prevent operational risks and achieve internal control objectives[168]. - The company has not identified any significant internal control deficiencies during the reporting period[169]. - The company maintained effective financial reporting internal control as of December 31, 2021[175]. - The company reported zero significant defects in both financial and non-financial reporting[174]. - There were no penalties imposed by securities regulatory authorities on directors, supervisors, or senior management in the past three years[144]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[181]. Future Outlook and Strategic Initiatives - The company aims for a GDP growth target of approximately 5.5% for 2022, amidst ongoing economic challenges[110]. - The company plans to enhance cash flow management and optimize debt structure to maintain a healthy financial status[112]. - The company is focusing on project development and sales to ensure sufficient cash flow for future growth[112]. - The company intends to strengthen management and operational efficiency to meet project timelines and quality standards[113]. - The company aims to reduce inventory and improve sales efficiency through market monitoring and flexible pricing strategies[114]. - The company is committed to deepening reforms and enhancing collaborative efforts in the biopharmaceutical sector[116]. - The company is focused on becoming a leading player in the regenerative medicine sector through strategic investments[116].

Financial Performance - The company's operating revenue for Q1 2022 was ¥476,659,221.01, a decrease of 41.82% compared to ¥819,251,680.11 in the same period last year[6] - The net profit attributable to shareholders for Q1 2022 was ¥132,669,907.73, down 51.49% from ¥273,513,197.92 year-on-year[6] - The company's basic earnings per share for Q1 2022 were ¥0.0437, a decrease of 51.17% from ¥0.0895 in the same period last year[6] - Net profit for the current period is ¥130,789,912.30, a decline of 51.7% compared to ¥271,122,247.85 in the previous period[29] - Earnings per share (EPS) for the current period is ¥0.0437, down from ¥0.0895 in the previous period[29] Cash Flow - The net cash flow from operating activities increased significantly to ¥158,851,768.09, compared to a negative cash flow of ¥1,151,781.35 in the previous year, representing an increase of 8,401.71%[6] - Cash flow from operating activities is ¥158,851,768.09, significantly improved from ¥1,868,468.77 in the previous period[32] - Cash and cash equivalents at the end of the period amount to ¥362,115,895.53, down from ¥724,350,456.31 in the previous period[34] - Investment activities resulted in a net cash outflow of ¥290,289,952.73, compared to a net inflow of ¥228,265,592.62 in the previous period[34] - Financing activities generated a net cash inflow of ¥269,466,533.97, contrasting with a net outflow of ¥172,737,449.10 in the previous period[34] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥15,973,555,307.74, reflecting a 3.44% increase from ¥15,442,762,867 at the end of the previous year[6] - Current assets amounted to CNY 12,367,695,388.52, up from CNY 11,838,639,442.96 at the start of the year, indicating a growth of approximately 4.48%[19] - The total liabilities of the company were CNY 6,760,834,546.00, compared to CNY 6,360,832,018.03 at the beginning of the year, representing an increase of approximately 6.3%[23] - The company’s total liabilities increased, with contract liabilities rising by 36.69% to ¥650,347,725.34, attributed to new project pre-sale funds[10] - The company experienced a 3599.24% increase in notes payable, reaching ¥410,555,211.10, primarily due to an increase in bank acceptance bills[10] Investments and Income - The company reported a significant increase in financial assets, with trading financial assets rising by 626.13% to ¥336,316,250.97 due to new wealth management products[10] - The company's investment income for Q1 2022 was negative at -¥813,363.39, a decline of 123.84% compared to the previous year, mainly due to reduced wealth management returns[11] - Other income for the current period is ¥107,672.33, a decrease from ¥205,746.79 in the previous period[27] Shareholder Information - The company had a total of 111,153 common shareholders at the end of the reporting period[13] - The company's equity attributable to shareholders rose to CNY 8,955,346,702.95 from CNY 8,822,676,795.23, marking an increase of about 1.5%[23] Inventory and Payables - Inventory levels stood at CNY 9,960,681,243.84, slightly up from CNY 9,923,035,697.37, indicating a marginal increase of approximately 0.38%[19] - Accounts payable decreased to CNY 2,046,275,384.03 from CNY 2,180,004,201.68, showing a decline of approximately 6.1%[22]

Group 1: Company Transformation and Strategy - The company does not rule out participating in mixed ownership reform, but will consider it only if it aligns with strategic development needs [2] - The acquisition of the Korean animation company REDROVER cost approximately 242 million RMB, and the company aims to enhance its cultural industry chain through this acquisition [2] - The company has been gradually reducing its debt since 2011, with a steady decline in the debt ratio, ensuring sufficient funding for transformation [3] Group 2: Financial Performance and Shareholder Returns - The company has not acquired land reserves for nearly four years, but the realizable asset volume is increasing based on the development progress of real estate projects [3] - In July 2015, the company implemented a dividend plan, distributing 3.00 shares for every 10 shares held and paying 2.00 RMB in cash per share [3] - The company plans to shift its financing strategy from short-term high-cost to long-term low-cost to maintain stable funding [4] Group 3: Future Directions and Market Position - The company will prioritize specialized areas in its health transformation efforts, integrating quality resources [4] - The management is committed to the transformation work, actively increasing their shareholdings and bringing in professional talent [4] - The company expects substantial progress in its three major transformation sectors, with a stable development outlook [4]

Sales Performance - The company reported good sales performance, particularly for the Nanjing Tianrun City and Venice Water City projects, which are located near Metro Line 3. The sales showed significant recovery following the opening of the metro on April 1, 2015 [2][3]. Fundraising and Financial Status - The company plans to issue non-public shares at a price not lower than 8.25 yuan per share, with a maximum of 557,575,757 shares to raise up to 4.6 billion yuan. The process is progressing as scheduled [3]. - The company is experiencing good sales and cash collection, leading to a gradual decrease in financing costs as previous high-cost financing is being repaid. The financing costs are considered low within the industry [3]. Current Projects - The company currently has several projects for sale, including Nanjing Venice Water City, Nanjing Tianrun City, Wuxi Beitang Project, Yixing Tianhui Yucheng, Wuhu City Light, and Jilin Green Valley Manor [3]. Strategic Transformation - 2015 is a crucial year for the company's strategic transformation, focusing on the integration of its real estate strengths with new sectors such as culture, health, and finance. The transformation efforts are being carried out systematically, supported by the company's resources [4].